PL358087A1 - Fapalpha-specific antibody with improved producibility - Google Patents

Fapalpha-specific antibody with improved producibility

Info

Publication number
PL358087A1
PL358087A1 PL99358087A PL35808799A PL358087A1 PL 358087 A1 PL358087 A1 PL 358087A1 PL 99358087 A PL99358087 A PL 99358087A PL 35808799 A PL35808799 A PL 35808799A PL 358087 A1 PL358087 A1 PL 358087A1
Authority
PL
Poland
Prior art keywords
fapalpha
specific antibody
improved producibility
producibility
improved
Prior art date
Application number
PL99358087A
Other languages
English (en)
Polish (pl)
Inventor
John Ewdard Park
Pilar Garin-Chesa
Uwe Bamberger
Wolfgang J. Rettig
Olivier Leger
Jose Saldanha
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL358087A1 publication Critical patent/PL358087A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL99358087A 1998-04-30 1999-04-22 Fapalpha-specific antibody with improved producibility PL358087A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98107925A EP0953639A1 (en) 1998-04-30 1998-04-30 FAPalpha-specific antibody with improved producibility

Publications (1)

Publication Number Publication Date
PL358087A1 true PL358087A1 (en) 2004-08-09

Family

ID=8231860

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99358087A PL358087A1 (en) 1998-04-30 1999-04-22 Fapalpha-specific antibody with improved producibility

Country Status (27)

Country Link
EP (2) EP0953639A1 (https=)
JP (1) JP4421779B2 (https=)
KR (1) KR100580936B1 (https=)
CN (1) CN1303430A (https=)
AR (1) AR016243A1 (https=)
AT (1) ATE356873T1 (https=)
AU (1) AU760305B2 (https=)
BG (1) BG65034B1 (https=)
BR (1) BR9910577A (https=)
CA (1) CA2327586C (https=)
CO (1) CO5050255A1 (https=)
DE (1) DE69935516T2 (https=)
EA (1) EA005401B1 (https=)
EE (1) EE200000642A (https=)
ES (1) ES2283114T3 (https=)
HU (1) HUP0101501A3 (https=)
ID (1) ID26555A (https=)
IL (1) IL138701A0 (https=)
NO (1) NO20005412L (https=)
NZ (1) NZ508456A (https=)
PL (1) PL358087A1 (https=)
SK (1) SK16192000A3 (https=)
TR (1) TR200003181T2 (https=)
UA (1) UA73276C2 (https=)
WO (1) WO1999057151A2 (https=)
YU (1) YU66300A (https=)
ZA (1) ZA200005506B (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
EP1268550A2 (en) * 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
EP2365004B1 (en) * 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
DK1534335T4 (en) * 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
DK1594955T3 (da) * 2003-02-14 2012-06-25 Biogen Idec Inc Ekspressionskassette og vektor til transient eller stabil ekspression af eksogene molekyler
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
PL2573114T3 (pl) 2005-08-10 2016-10-31 Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
CA2631184A1 (en) * 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1806365A1 (en) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
WO2008105886A2 (en) 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
KR20090100461A (ko) 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
ES2840725T3 (es) * 2007-08-20 2021-07-07 Glaxo Group Ltd Procedimiento de producción
CN101896818B (zh) * 2007-12-10 2016-01-20 霍夫曼-拉罗奇有限公司 作为癌症的标记物的Seprase
EP2071337A1 (en) * 2007-12-10 2009-06-17 F.Hoffmann-La Roche Ag Seprase as a marker for cancer
CN101896817A (zh) * 2007-12-10 2010-11-24 霍夫曼-拉罗奇有限公司 用于结直肠癌的标记物组
WO2009117289A2 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
ES2589912T3 (es) 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
SG179135A1 (en) 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2806021C (en) * 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
RS59700B1 (sr) * 2014-03-26 2020-01-31 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
CN105646710B (zh) * 2014-11-17 2020-08-25 四川科伦博泰生物医药股份有限公司 一种全人源化抗vegfr-2单克隆抗体及其制备方法
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
WO2017132615A1 (en) * 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
GEP20227398B (en) 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CN116474108A (zh) * 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
CN110526979A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN110526991A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN109053893B (zh) * 2018-08-15 2021-03-30 智享生物(苏州)有限公司 一种抗d-二聚体单克隆抗体及其制备方法
CN112972675A (zh) * 2018-09-07 2021-06-18 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
FI3997103T3 (fi) 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö
JP7801207B2 (ja) 2019-07-08 2026-01-16 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
US12371491B2 (en) 2019-09-03 2025-07-29 Bio-Thera Solutions, Ltd. Anti-TIGIT immunosuppressant and application thereof
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
WO2021219092A1 (en) * 2020-04-30 2021-11-04 I-Mab Biopharma Co., Ltd. Pharmaceutical compositionscontaining anti-cd47 antibodies
WO2021236658A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
CN112540176B (zh) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
IL300534A (en) * 2020-08-11 2023-04-01 Kanaph Therapeutics Inc A fusion protein containing 12-il and an anti-fap antibody, and its use
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
IL303925A (en) 2021-01-07 2023-08-01 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
WO2023031644A1 (en) 2021-08-31 2023-03-09 Full-Life Technologies Limited Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof
CN118974258A (zh) * 2021-12-30 2024-11-15 乐普创一生物科技（上海）有限公司 抗fap-alpha的人源抗体
EP4578877A1 (en) 2022-08-03 2025-07-02 Nanjing Leads Biolabs Co., Ltd. Antibody fusion protein targeting fap and tgf-beta, and use thereof
CN120112308A (zh) 2022-10-07 2025-06-06 吉尼松公司 使用抗fap car-t细胞免疫治疗骨骼肌病
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN120309735A (zh) * 2024-01-15 2025-07-15 迈威(上海)生物科技股份有限公司 重组抗fap抗体及其应用
CN118496382B (zh) * 2024-05-22 2025-01-07 山东第一医科大学附属省立医院(山东省立医院) 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用
CN118812715A (zh) * 2024-07-02 2024-10-22 国睿(广州)生物科技有限公司 一种靶向成纤维活化蛋白α的纳米抗体及其应用
CN119265201A (zh) * 2024-08-23 2025-01-07 中国人民解放军海军军医大学第一附属医院 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059523A (en) * 1988-05-02 1991-10-22 Sloan-Kettering Institute For Cancer Research Cell-surface glycoproteins of human sarcomas
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1993005804A1 (en) * 1991-09-18 1993-04-01 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
ZA936260B (en) * 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
CA2248653C (en) * 1996-05-01 2003-08-12 Genitope Corporation Vaccines for treatment of lymphoma and leukemia

Also Published As

Publication number Publication date
DE69935516T2 (de) 2008-01-31
EA005401B1 (ru) 2005-02-24
KR20010042826A (ko) 2001-05-25
EA200001023A1 (ru) 2001-06-25
CA2327586A1 (en) 1999-11-11
ES2283114T3 (es) 2007-10-16
UA73276C2 (en) 2005-07-15
EE200000642A (et) 2002-04-15
YU66300A (sh) 2004-03-12
CN1303430A (zh) 2001-07-11
ID26555A (id) 2001-01-18
JP4421779B2 (ja) 2010-02-24
CA2327586C (en) 2013-02-26
EP0953639A1 (en) 1999-11-03
AR016243A1 (es) 2001-06-20
NO20005412L (no) 2000-12-06
BG65034B1 (bg) 2006-12-29
DE69935516D1 (de) 2007-04-26
AU4032299A (en) 1999-11-23
KR100580936B1 (ko) 2006-05-17
WO1999057151A2 (en) 1999-11-11
TR200003181T2 (tr) 2001-04-20
BR9910577A (pt) 2001-09-11
EP1098979B1 (en) 2007-03-14
JP2002513556A (ja) 2002-05-14
EP1098979A2 (en) 2001-05-16
CO5050255A1 (es) 2001-06-27
IL138701A0 (en) 2001-10-31
HUP0101501A2 (hu) 2001-08-28
BG104828A (en) 2001-09-28
AU760305B2 (en) 2003-05-15
NO20005412D0 (no) 2000-10-27
WO1999057151A3 (en) 2000-03-16
ZA200005506B (en) 2002-05-14
HUP0101501A3 (en) 2004-01-28
NZ508456A (en) 2004-03-26
ATE356873T1 (de) 2007-04-15
SK16192000A3 (sk) 2001-04-09

Similar Documents

Publication Publication Date Title
PL358087A1 (en) Fapalpha-specific antibody with improved producibility
GB9809839D0 (en) Antibody
EP1073464A4 (en) MONOCLONAL ANTIBODIES WITH REDUCED IMMUNIZABILITY
ZA995897B (en) Waveguides having axially varying structure.
GB9911569D0 (en) Antibodies
IT1306854B1 (it) Autoveicolo con capote apribile.
GB9818915D0 (en) Antibodies
PL333742A1 (en) Compression -ignition engine
GB9819411D0 (en) Antibodies
AU137569S (en) Gate
GB2342394B (en) Engine
GB2346928B (en) Latch element
GB2322398B (en) Gate
GB9800760D0 (en) Antigens
GB9816327D0 (en) Antibody
HU1616U (en) Lock with increasing closing-number
GB9816280D0 (en) Antibody combination
HU1601U (en) Chopping-board with collector
ZA952269B (en) Antibody conjugates with improved properties
HU1694U (en) Pile-wall structure with end-tenon
ZA988004B (en) Gate assembly
GB9818923D0 (en) Burnerless combustion
GB9827916D0 (en) Fuel effect
GB9822143D0 (en) Antigens
GB9819015D0 (en) Antigens

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)
VDSO Invalidation of derivated patent or utility model

Ref document number: 380319

Country of ref document: PL